1. Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers

Date: 2018-06-19 | ID: 10000487

Résumé: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula IA or Formula IB, as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof. For Formula IA and Formula IB compounds A1, A2, A3, A4, W1, W2, Y, X, R1, R2, R3, R4a, R4b, R5a, R5b, R6, R7, R8, R9, R9a, R9b, R10 and subscript n are as defined in the specification. The inventive Formula IA and Formula IB compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

2. Flame retarding agent, flame-retardant aqueous resin composition and flame-retardant urethane resin composition containing said flame-retarding agent, and use therefor

Date: 2018-06-19 | ID: 10000625

Résumé: The present invention relates to a flame-retarding agent comprising a phosphoramidate compound represented by Formula (I): wherein R1 and R2 are each independently C1-3 alkyl, R11 and R12 are each independently C1-3 alkylene, R13 is C1-6 alkylene, B1 is hydrogen or C1-6 alkyl, and A is hydrogen or an organic group represented by Formula (Ia): wherein R3 and R4 are each independently C1-3 alkyl, R14 and R15 are each independently C1-3 alkylene, and B2 is hydrogen or C1-6 alkyl, wherein when B1 is C1-6 alkyl, and A is hydrogen, B1 and R13-A, taken together with nitrogen to which they are attached, may form a non-aromatic nitrogen-containing heterocycle, and wherein when B1 is C1-6 alkyl, A is an organic group represented by Formula (Ia), and B2 is C1-6 alkyl, B1 and B2, taken together with nitrogen to which they are attached and with R13, may form a non-aromatic nitrogen-containing heterocycle.

3. Method for predicting failure of a light-emitting diode

Date: 2018-06-19 | ID: 10001522

Résumé: A method for predicting failure of a light-emitting diode, includes applying a test potential difference across the terminals of the light-emitting diode lower than its minimum drive potential difference, the test potential difference having the same sign as the minimum drive potential difference; measuring the current Ic flowing through the light-emitting diode during the application of the test potential difference; and generating an alarm signal when the measured current Ic exceeds an alarm threshold Ia.

4. Photopolymer formulation for production of holographic media comprising borates with

low TG

Date: 2018-06-19 | ID: 10001703

Résumé: The invention relates to a photopolymer formulation comprising a component reactive toward isocyanates, a polyisocyanate component, a writing monomer and a photoinitiator containing at least one dye and a coinitiator, characterized in that the coinitiator contains at least one substance of the formula (Ia)The invention further provides a process for preparing the specific coinitiators and the coinitiators obtainable by this process, and additionally a process for producing a holographic medium using the specific coinitiators, and a holographic medium obtainable using the inventive photopolymer formulation. The invention further relates to a laminate structure comprising an inventive holographic medium and likewise specific borates suitable as coinitiators.

5. Power conversion device

Date: 2018-06-19 | ID: 10003277

Résumé: A power converter including a compressor as a load includes a compensation current output (80) allowing compensation current (Ic), which compensates for leakage current (Ia), to flow. A controller (50) receives a detection signal from a rotational speed sensor (55) which senses the rotational speed of the compressor (CM). When the rotational speed has increased to a set rotational speed at which the leakage current (Ia) is lower than or equal to its limiting value (Lmax) (e.g., the limiting value specified under the Electrical Appliances and Materials Safety Act or by the IEC) in a state where the compensation current output (80) is off, the compensation current output (80) is switched from an on state to an off state. This may reduce the leakage current from the compressor with low power loss.

6. Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof

Date: 2018-06-26 | ID: 10004750

Résumé: The present invention provides an acid addition salt or a sodium salt of a compound represented by the formula (IA): or their hydrate or a stable crystalline solid thereof. The salt or the crystalline solid is extremely useful as an active ingredient for the production of a pharmaceutical product.

7. Anticancer agent

Date: 2018-06-26 | ID: 10005752

Résumé: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each

symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.

8. Device, system and method for illuminating a target area

Date: 2018-07-03 | ID: 10011356

Résumé: An illumination device (6) comprising a light source (8) producing a first cone of light (10) and a deflection unit (12) for the beam-shaping conversion of the first cone of light (10) into a second cone of light (14a,b) and to emit the latter towards the target area (4a,b), the deflection unit (12) can be varied in order to vary the form (Fa,b) and/or the intensity distribution (Ia,b) in the second cone of light.An illumination system (2) contains the illumination device (6) and the target area (4a,b).The illumination device (6) or the illumination system (2) is used to illuminate a surface of an interior of a vehicle as target area (4a,b).

9. Adsorbent for desulfurization of gasoline and method for desulfurization of gasoline

Date: 2018-07-03 | ID: 10011779

Résumé: The present invention provides an adsorbent and a method for desulfurization of gasoline. The adsorbent is obtained by loading active metal component on a composite carrier comprising zeolite and active carbon subjected to alkali treatment respectively, the active metal is selected from one or more elements of IA, IIA, VIII, IB, IIB and VIB groups in the periodic table. This method uses the adsorbent to conduct gasoline adsorption desulfurization, which especially cuts the gasoline into a light and a heavy gasoline fraction firstly, then the light fraction is subjected to adsorption desulfurization using the adsorbent, and the heavy fraction is subjected to selective hydrodesulfurization, a cutting temperature of the light and the heavy gasoline fraction is 70-110° C. The adsorbent has a large sulfur adsorption, a long service life, and simply to be regenerated; the method can realize deep desulfurization of gasoline, and has a less octane number loss.

10. Compounds, compositions, and methods for increasing CFTR activity

Date: 2018-07-10 | ID: 10017503

Résumé: The disclosure encompasses compounds having e.g., Formula (Ia) or (Ib), compositions thereof, and methods of modulating CFTR activity. The disclosure also encompasses methods of treating a condition associated with CFTR activity or condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a compound of Formula (I) or (Ib).

11. Substituted 5-hydroxy-2,3-diphenylpentanonitrile derivatives, processes for their preparation and their use as herbicides and/or plant growth regulators

Date: 2018-07-17 | ID: 10021877

Résumé: Primarily, the present invention relates to the use of substances of the formula (I) as herbicides, in particular for controlling broad-leaved weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influencing the growth of crops of useful plants. The invention furthermore relates to the novel herbicidal substances of the formulae (Ib) and (Ia). The present invention also relates to corresponding compositions comprising one or more of the herbicides of the formula (I) and further agrochemically active substances, and also to plant growth-regulating or herbicidal compositions comprising one or more of these compounds. Moreover, the present invention relates to processes for preparing the compounds of the formula (I).

12. Spirocyclic morphinans and use thereof

Date: 2018-07-24 | ID: 10030021

Résumé: In one aspect, the invention provides compounds of Formula I: (I) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, Y, Za are defined as set forth in the disclosure. The invention also provides compounds of any one of Formulae II to VII, IA to IC, and IIA to IIC, and pharmaceutically acceptable salts and solvates thereof. Other aspects of the invention include the use of compounds of Formulae I to VII, IA to IC, and IIA to IIC, and pharmaceutically acceptable salts and solvates thereof for the treatment of disorders responsive to modulation of one or more opioid receptors. In certain embodiments, the Compounds of the Invention are useful for treating pain.

13. Diagnosis and treatment of invasive aspergillosis

Date: 2018-07-24 | ID: 10031125

Résumé: Methods for diagnosing, treating, and monitoring the treatment of invasive aspergillosis (IA) are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having IA.

14. Pressure detecting device and touch panel

Date: 2018-07-24 | ID: 10031606

Résumé: The invention provides a pressure detecting device containing a pressurized member having a contact surface that is subjected to pressure due to contact with a pressurizing means; and a piezoelectric member that is arranged facing the pressurized member and that includes a polymeric piezoelectric material having a piezoelectric constant d14 of 1 pm/V or more as measured by a displacement method at 25° C., and a ratio IEb/IEa between a product IEb of a cross-sectional secondary moment Ib and a Young's modulus Eb of the pressurized member, and a product IEa of a cross-sectional secondary moment Ia and a Young's modulus Ea of the piezoelectric member, is in a range of from 102 to 1010.

15. Sulfide solid electrolyte material, battery, and producing method for sulfide solid electrolyte material

Date: 2018-07-24 | ID: 10033065

Résumé: A main object of the present invention is to provide a sulfide solid electrolyte material having favorable ion conductivity and low reduction potential. The present invention solves the above-mentioned problem by providing a sulfide solid electrolyte material including an M1 element (such as a Li element), an M2 element (such as a Ge element, a Si element and a P element) and a S element, wherein the material has a peak at a position of 2=29.58°±0.50° in X-ray diffraction measurement using a CuK line; and when a diffraction intensity at the peak of 2=29.58°±0.50° is regarded as IA and a diffraction intensity at a peak of 2=27.33°±0.50° is regarded as IB, a value of IB/IA is less than 0.50, and M2 contains at least P and Si.

16. Flame-retardant expandable polymers

Date: 2018-07-31 | ID: 10035892

Résumé: The present relates to flame-retardant expandable polymers and to polymer foams and to the use thereof. These flame-retardant expandable polymers and polymer foams can be contained in one or several pressurized containers. According to the present, at least one of the following phosphorus compounds is used as a flame retardant: phosphorus compound according to formula (Ia): (Ia) 10-hydroxy-9, 10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide (DOPO-OH); or the salts thereof according to formula (Ib): (Ib) (DOPO-OR); or the ring-opened hydrolysates thereof according to formula (Ic): (Ic).

17. Inhibitors of influenza viruses replication

Date: 2018-08-07 | ID: 10039762

Résumé: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

18. Process for producing a fuel cell electrode catalyst, fuel cell electrode catalyst and use thereof

Date: 2018-08-07 | ID: 10044045

Résumé: Provided is a process for producing a fuel cell electrode catalyst with high catalytic activity that is alternative to a noble metal catalyst, through a heat treatment at a relatively low temperature. A process for producing a fuel cell electrode catalyst includes a step (I) of obtaining a catalyst precursor, including a step (Ia) of mixing at least a metal compound (1), a nitrogen-containing organic compound (2), and a fluorine-containing compound (3), and a step (II) of heat-treating the catalyst precursor at a temperature of 500 to 1300° C. to obtain an electrode catalyst, a portion or the entirety of the metal compound (1) being a compound containing an atom of a metal element M1 selected from the group consisting of iron, cobalt, chromium, nickel, copper, zinc, titanium, niobium and zirconium, and at least one of the compounds (1), (2) and (3) containing an oxygen atom.

19. Frame transmission system and method of interference alignment and controlling in multi-cell random access network

Date: 2018-08-07 | ID: 10045240

Résumé: Provided is a frame transmission method of interference alignment (IA) and controlling, the method including calculating a channel matrix of a basic service set (BSS) by measuring channel information between an access point and a user terminal, performing singular value decomposition (SVD) based on the calculated channel matrix, selecting a beamforming vector in consideration of an interference amount associated with another access point based on the SVD performed by the channel matrix, and calculating a leakage interference (LIF) value based on the selected beamforming vector.

20. Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Date: 2018-08-14 | ID: 10047083

Résumé: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

21. Liquid-crystalline medium

Date: 2018-08-14 | ID: 10047292

Résumé: The invention relates to a liquid-crystalline medium, characterized in that it comprises one or more compounds of the formula IA, and one or more compounds of the formula IB, in which RA, RB, XA, XB and Y1-13 have the meanings indicated in claim 1, and to the use thereof for electro-optical purposes, in particular for shutter glasses, 3D applications, in TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, PS-FFS and PS-VA-IPS displays.

22. Network node and method for enabling interference alignment of transmissions to user equipments

Date: 2018-08-14 | ID: 10050734

Résumé: A method performed by a network node for enabling Interference Alignment, IA, of transmissions to user equipments is provided. The network node receives signal strength values associated with more than one network node for the user equipments, wherein each signal strength value is associated with one network node. Then, the network node schedules a first group of the user equipments on radio transmission resources that are orthogonal to radio transmission resources of at least one other group of the user equipments when an IA gain value for each user equipment in the first group passes a threshold level. The IA gain value is determined by the network node based on the received signal strength values. The network node may then enable IA of transmissions to the scheduled first group of user equipments from at least two network nodes capable of performing IA of transmissions.

23. Compounds and their use as BACE inhibitors

Date: 2018-08-21 | ID: 10053453

Résumé: The present application relates to compounds of formula (I), (Ia), or (Ib) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing A-related pathologies such as Down's syndrome, -amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (mild cognitive impairment), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia, including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.

24. Process for preparing chiral dipeptidyl peptidase-IV inhibitors

Date: 2018-08-21 | ID: 10053466

Résumé: A process for preparing a compound of structural Formula Ia:

25. Imidazo[1,2-]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto

Date: 2018-08-28 | ID: 10058549

Résumé: rmidazo[1,2-]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia, dyssomnia, parasomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic- related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to methods for the treatment of 5-HT2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.

26. Imidazolidinedione derivatives

Date: 2018-08-28 | ID: 10058551

Résumé: The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.

27. Sialon sintered body and cutting insert

Date: 2018-08-28 | ID: 10058925

Résumé: A sialon sintered body and a cutting insert each having thermal shock resistance and VB wear resistance. The sialon sintered body and the cutting insert contain -sialon and 21R-sialon and exhibit an X-ray diffraction peak intensity ratio [(I21R/IA)×100] of 5% or greater and smaller than 30%, wherein IA represents the sum of the peak intensities of the sialon species, and I21R represents the peak intensity of 21R-sialon, the ratio being calculated from the peak intensities of the sialon species obtained by using X-ray diffractometry.

28. Heterogeneous catalysts for the transesterification of aromatic alcohols; and methods of making and use thereof

Date: 2018-08-28 | ID: 10059652

Résumé: Disclosed herein are new mixed metal oxide catalysts suitable as heterogeneous catalysts for catalyzing the transesterification process of aromatic alcohols with a dialkyl carbonate to form aromatic carbonates. The heterogeneous catalyst comprises a combination of two, three, four, or more oxides of Mo, V, Nb, Ce, Cu, Sn, or an element selected from Group IA or Group IIA of the periodic table.

29. Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof

Date: 2018-09-04 | ID: 10064848

Résumé: Compounds for the preparation of pyridone derivatives are provided. In particular, compounds of formula (IA) are provided, wherein the variable groups are as defined in the specification. The compounds of formula (IA) can be used as intermediates in the preparation of pyridone derivatives useful as mitogen-activated protein kinase kinase (MEK) inhibitors and therapeutic agents for treating cancer.

30. Substituted imidazo[4,5-c]pyridines as SSAO inhibitors

Date: 2018-09-04 | ID: 10065954

Résumé: Specific compounds of formula (Ia): and pharmaceutically acceptable salts thereof. Pharmaceutical compositions of the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof. A method for inhibiting tumor growth in a subject that includes administering to the subject an effective amount of a compound selected from the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof. A method for modulating semicarbazide-sensitive amine oxidase activity in a subject that includes administering to the subject an effective amount of a compound selected from the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof.

31. Pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors

Date: 2018-09-04 | ID: 10065964

Résumé: The present invention relates to compounds of formula (Ia), (Ib) or (Ic): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma, COPD, allergic rhinitis, chronic sinusitis, atopic dermatitis, psoriasis, rosacea, alopecia, allergic conjunctivitis and dry eye disease.

32. Alkyd resin compositions

Date: 2018-09-04 | ID: 10066053

Résumé: The present invention relates to an alkyd resin composition comprising a. 1-60 wt % of an imide compound according to anyone of formulas Ia, Ib, Ic, Id or Ie wherein R1 is H or a C1-C20 optionally substituted hydrocarbon group; R2 and R5 are independently H, or a C1-C20 hydrocarbon group; R3 and R4 are independently H, or a C1-C20 hydrocarbon group; R6 is H or a methyl group; R7 and R8 are independently H, methyl or ethyl; b. 10-40 wt % of an alcohol having a number average hydroxy functionality 2.0; c. 30-70 wt % of fatty acids or vegetable oils; d. 0-50 wt % of a mono and/or polyfunctional compound capable of esterification, which compound is different from the compounds used in a, b and c; wherein the wt % is determined relative to the total of weight of compounds a, b, c and d.

33. Polymeric ion conductor with improved thermal characteristics

Date: 2018-09-04 | ID: 10066068

Résumé: The present disclosure provides polymers comprising at least one repeat unit represented by any one of structural formulas (IA)-(IE) disclosed herein, for example: Values for the variables are as disclosed herein. The polymers provided can be employed as ion conductors, for example in fuel cells, and have improved thermal characteristics.

34. Intellectual asset family creation

Date: 2018-09-04 | ID: 10068300

Résumé: An example embodiment includes a method for creating a family of related intellectual asset (IA) records. The method may include obtaining IA data for a current filing. The method may include creating an IA record for the current filing. The method may include obtaining IA data for one or more related filings. The current filing and the one or more related filings belong to a family of intellectual assets. The method may also include preparing for creation of a plurality of IA records for the one or more related filings based on the IA data for the current filing and the IA data for the one or more related filings. The method may further include creating a plurality of new IA records for the one or more related filings.

35. Therapeutic compounds

Date: 2018-09-11 | ID: 10071985

Résumé: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

36. Compounds and methods for the treatment of cystic fibrosis

Date: 2018-09-11 | ID: 10072017

Résumé: The invention relates to a compound of Formula I or IA compositions comprising compounds of Formula I or IA, and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof:

37. Diarylethene compounds and uses thereof

Date: 2018-09-11 | ID: 10072023

Résumé: A compound according to Formula IA and IB, reversibly convertible under photochromic and electrochromic conditions between a ring-open isomer A and a ring-closed isomer B is provided. For substitutent groups, Z is N, O or S; each R1 is independently selected from the group consisting of H, or halo; each R2 is independently selected from the group consisting of H, halo, a polymer backbone, alkyl or aryl; or, when both R2 together form CHCH and form part of a polymer backbone; each R3 is independently selected from the group consisting of H, halo, alkyl, alkoxy, thioalkyl or aryl; each R4 is aryl; and each R5 is independently selected from the group consisting of H, halo, alkyl, alkoxy, thioalkyl or aryl.

38. Non-ionic compound, resin, resist composition and method for producing resist pattern

Date: 2018-09-11 | ID: 10073343

Résumé: A compound which is non-ionic compound, the compound has a group represented by formula (Ia): wherein R2 represents a group having a C3 to C18 alicyclic hydrocarbon group where a methylene group may be replaced by an oxygen atom or a carbonyl group, Rf1 and Rf2 each independently represent a C1 to C4 perfluoroalkyl group, and * represents a binding site.

39. Tricyclic prodrugs

Date: 2018-09-18 | ID: 10077246

Résumé: Prodrugs (I) and (Ia) of galiellactone, and derivatives thereof, are provided by reacting the parent compound, e.g. galiellactone, with a thiol. Such drugs may be administered orally to treat cancer and other proliferative diseases.

40. Read-through compound prodrugs suppressing premature nonsense mutations

Date: 2018-09-18 | ID: 10077260

Résumé: Premature termination codon readthrough prodrug compounds, compositions thereof, and methods of making and using the same are provided. In certain embodiments, the compounds are of Formula Ia or a pharmaceutically acceptable salt, solvate, polymorph, hydrate, ester, isomer, stereoisomer, or tautomer thereof, wherein R, A and W are as described herein.

41. Temperature detection apparatus and rotation angle detection apparatus

Date: 2018-09-18 | ID: 10078018

Résumé: A temperature detection apparatus and a rotation angle detection apparatus are provided that allow a temperature of a resolver to be calculated in real time. A rotation angle detection apparatus (10) (temperature detection apparatus) includes a resolver (20) with an excitation coil and output coils wound thereon, the excitation coil being subjected to an excitation voltage (VA) and the output coil outputting voltage signals (VB, VC) corresponding to the excitation voltage (VA), and a temperature calculation circuit (sensor microcomputer (32)) that detects a phase of the excitation voltage (VA) and that detects a phase of an excitation current (IA). The temperature calculation circuit (sensor microcomputer (32)) calculates a temperature of the resolver (20) based on a phase difference between the excitation voltage (VA) and the excitation current (IA).

42. Dither current power supply control method and dither current power supply control apparatus

Date: 2018-09-18 | ID: 10079087

Résumé: In the dither current power supply control method, in order to prevent occurrence of a difference between the target average current and the detected average current, which is caused when a medium current (I0) between a dither large current (I2) and a dither small current (I1) and a waveform average (Ia) of the dither current are different from each other depending on a response time difference (ab) between a rise time (b) and a fall time (a) of the dither current, negative feedback control is carried out by using a command medium current corresponding to the target average current corrected by a correction parameter based on experimentally measured data, thereby suppressing occurrence of a transient fluctuation error by the negative feedback control, so that a highly precise and stable load current is acquired.

43. Substituted benzoxazine and related compounds

Date: 2018-10-02 | ID: 10087151

Résumé: The present invention relates to compounds including but not limited to of any one of formulas Ia, Ib, IIa, IIb, IIIa, IIIb, and IV to VI, VIIa, VIIb, VIIIa, VIIIb and VIIIc as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.

44. Inference alignment (IA) method for uplink in wireless local area network (WLAN) system, access point (AP) and user terminal for performing the same

Date: 2018-10-02 | ID: 10091794

Résumé: An interference alignment (AI) method for an uplink in a wireless local area network (WLAN) system, an access point (AP) and a user terminal for performing the same, and the AP that may select an interference space, broadcast information on the selected interference space, select a user terminal to be assigned a data transmission opportunity based on leakage of interference (LIF) information received from at least one user terminal, receive data from the user terminal, and decode the data using a minimum square error (MMSE) based receiving filter.

45. Process for the preparation of substituted phenoxyphenyl ketones

Date: 2018-10-09 | ID: 10093634

Résumé: The present invention relates to a process for the preparation of the ketone compounds (IA) and their use as intermediates for the preparation of triazole fungicides.

46. Hepatic stellate cell precursors and methods of isolating same

Date: 2018-10-09 | ID: 10093895

Résumé: The present invention relates to precursor cells to hepatic stellate cells, compositions comprising same and methods of isolating same. The surface antigenic profile of the precursors is MHC class Ia negative, ICAM-1+, VCAM-1+, 3-integrin+. In addition to expression of these surface markers, the cells also express the intracellular markers desmin, vimentin, smooth muscle -actin, nestin, hepatocyte growth factor, stromal derived factor-1 and Hlx homeobox transcriptional factor.

47. Resin, resist composition and method for producing resist pattern

Date: 2018-10-16 | ID: 10101657

Résumé: A resist composition contains: a resin having an acid-labile group, a resin having a structural unit represented by formula (I), an acid generator, and a solvent; wherein Ri41 represents a hydrogen atom or a methyl group, Ri42 represents a C1 to C10 hydrocarbon group that may be substituted with a hydroxy group, a C2 to C7 acyl group or a hydrogen atom, Ri43 in each occurrence independently represents a C1 to C6 alkyl group or a C1 to C6 alkoxy group, p represents an integer of 0 to 4, Z represents a divalent C3 to C20 hydrocarbon group having a group represented by formula (Ia), and a methylene group contained in the hydrocarbon group may be replaced by an oxygen atom, a sulfur atom or a carbonyl group, *[(CH2)wO]r (Ia): wherein w and r each independently represents an integer of 1 to 10, and * represent a bonding position.

48. Mobile terminal and controlling method thereof

Date: 2018-10-16 | ID: 10104208

Résumé: Disclosed are a mobile terminal for providing an intelligent agent (IA) service and controlling method

thereof. The mobile terminal includes a display unit, a camera, a sensing unit comprising a microphone configured to sense a surrounding voice of the mobile terminal, an angle sensor configured sense an angle of the mobile terminal, and a location sensor configured to sense a location of the mobile terminal, a communication unit configured to transmit/receive data with a server configured to store a context information of a user, and a controller, if a trigger signal including a preset voice signal is sensed through the microphone, activating an intelligent agent (IA), the controller, if a preset input signal is sensed in a state that the IA is activated, activating the camera.

49. Thermal spray material, thermal spray coating and thermal spray coated article

Date: 2018-10-23 | ID: 10106466

Résumé: This invention provides a thermal spray material capable of forming a thermal spray coating excellent in plasma erosion resistance as well as in properties such as porosity and hardness. The thermal spray material comprises a rare earth element oxyhalide (RE-OX) which comprises a rare earth element (RE), oxygen (O) and a halogen atom (X) as its elemental constituents. The thermal spray material has an X-ray diffraction pattern that shows a main peak intensity IA corresponding to the rare earth element oxyhalide, a main peak intensity IB corresponding to a rare earth element oxide and a main peak intensity IC corresponding to a rare earth element halide, satisfying a relationship [(IB+IC)/IA]<0.02.

50. Monothiol mucolytic agents

Date: 2018-10-23 | ID: 10106551

Résumé: Provided are mucolytic agents represented by formula (Ia)-(Id): where the structural variables R1, R2, R5 and R6 are as defined herein. Also provided are a variety of methods of treatment which take advantage of the mucolytic properties of the compounds represented by formula (Ia)-(Id).

51. Mixed cathode material with high energy density

Date: 2018-10-23 | ID: 10109846

Résumé: The present invention relates to an electrochemical cell comprising an anode of a Group IA metal and a cathode of a composite material prepared from a first active cathode material of a transition metal phosphate mixed or added to a second active cathode material of a carbonaceous material. The cathode material of the present invention provides increased rate pulse performance compared to carbon monofluoride cathode material. In addition, the cathode material of the present invention is chemically stable which makes it particularly useful for applications that require increased rate capability in extreme environmental conditions such as those found in oil and gas exploration.

52. P2X7 modulators and methods of use

Date: 2018-10-30 | ID: 10112937

Résumé: The present invention is directed to compounds of Formulas (I, Ia, IIa and IIb). The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, Ia, IIa and IIb). Methods of making and using the compounds of Formulas (I, Ia, IIa and IIb) are also within the scope of the invention.

53. Benzodiazepine dimers, conjugates thereof, and methods of making and using

Date: 2018-10-30 | ID: 10112975

Résumé: Benzodiazepine dimers having a structure represented by wherein R1 is wherein the variables in formulae (I), (Ia), and (Ib) are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used in an antibody-drug conjugate (ADC).

54. Adeno-associated virus vectors for treatment of glycogen storage disease

Date: 2018-10-30 | ID: 10113183

Résumé: The present disclosure describes improved adeno-associated virus (AAV) vectors for gene therapy applications in the treatment of glycogen storage disease, particularly glycogen storage disease type Ia (GSD-Ia). Described are recombinant nucleic acid molecules, vectors and recombinant AAV that include a G6PC promoter/enhancer, a synthetic intron, a G6PC coding sequence (such as a wild-type or codon-optimized G6PC coding sequence), and stuffer nucleic acid sequence situated between the G6PC promoter/enhancer and the intron, as well as between the intron and the G6PC coding sequence. The recombinant AAVs disclosed herein exhibit highly efficient liver transduction and are capable of correcting metabolic abnormalities in an animal model of GSD-Ia.

55. Apparatus, system and method for initiation of buried explosives

Date: 2018-10-30 | ID: 10113843

Résumé: An initiator apparatus (IA) for blasting, the apparatus including: a magnetic receiver for receiving a magnetic communication signal through the ground by detection of a magnetic field; a controller, in electrical communication with the magnetic receiver, for processing the magnetic communication signal to determine a command for blasting; and a light source in electrical communication with the controller for generating a light beam to initiate a light-sensitive explosive (LSE) in accordance with the command.

56. Arginase inhibitors and methods of use

Date: 2018-11-06 | ID: 10118936

Résumé: The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: or a

pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.

57. Stable 2,3,3,3-tetrafluoropropene composition

Date: 2018-11-06 | ID: 10119055

Résumé: A stable composition (CS) including at least x wt.-% 2,3,3,3-tetrafluoropropene (99.8 ÿ x<100), at most y wt.-% unsaturated compound(s) (Ia) (0<y ÿ 0.2) selected from among 3,3,3-trifluoropropene (HFO-1243zf) and the positional isomers of 2,3,3,3-tetrafluoropropene, such as 1,3,3,3-tetrafluoropropene (isomers Z and E) and 1,1,2,3-tetrafluoropropene, and, optionally, at most 500 ppm of 3,3,3-trifluoropropyne and/or at most 200 ppm 1,1,1,2,3-pentafluoropropene (HFO-1225ye).

58. Sulfide solid electrolyte material, battery, and method for producing sulfide solid electrolyte material

Date: 2018-11-13 | ID: 10128532

Résumé: Sulfide solid electrolyte material with favorable ion conductivity, wherein charge and discharge efficiency is inhibited from decreasing. Solves problem by providing a sulfide solid electrolyte material including a Li element, Si element, P element, S element and O element, having peak at position of 2=29.58°±0.50° in X-ray diffraction measurement using CuK ray, wherein sulfide solid electrolyte material does not have peak at position of 2=27.33°±0.50° in X-ray diffraction measurement using CuK ray, or in case of having peak at position of 2=27.33°±0.50°, value of IB/IA is 1 or less when diffraction intensity at peak of 2=29.58°±0.50° is regarded as IA and diffraction intensity at peak of 2=27.33°±0.50° is regarded as IB; and wherein molar fraction of O element to total of S element and O element is larger than 0.2.

59. Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals

Date: 2018-11-20 | ID: 10130635

Résumé: The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals. In particular, the present invention concerns enantiomerically pure optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives represented by formula (IA) and (IB), processes for preparing the alcohol derivatives and their use in preparing pharmaceuticals.

60. Heterodimers of glutamic acid

Date: 2018-11-20 | ID: 10131627

Résumé: Compounds of Formula (Ia) wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C6 substituted or unsubstituted alkyl or NRR,

61. 5 phosphate mimics

Date: 2018-11-20 | ID: 10131908

Résumé: The present invention provides nucleosides and oligonucleotides comprising a 5 phosphate mimics of formula (IVc) or (Vc), One aspect of the present invention relates to modified nucleosides and oligonucleotides comprising such dinucleotide of formula (Ia). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.

62. Method and apparatus for performing wireless communication based on heterogeneous interference alignment (IA) scheme in wireless local area network (WLAN)

Date: 2018-11-20 | ID: 10136348

Résumé: Provided is a method and apparatus for performing a wireless communication based on a heterogeneous interference alignment (IA) scheme for a downlink multi-user multiple-input and multiple-output (DL MU-MIMO) communication in a wireless local area network (WLAN), and a wireless communication method employing a hybrid scheme that may include storing maximum throughputs of IA schemes, measuring an environment of a wireless network, calculating predicted throughputs of the IA schemes based on the measured environment of the wireless network, selecting an IA scheme from among the IA schemes based on the predicted throughputs, and communicating with a user terminal based on the selected IA scheme.

63. Benzomorphan analogs and the use thereof

Date: 2018-11-27 | ID: 10138207

Résumé: The present invention is directed to Benzomorphan Analog compounds of the Formula I, Formula IA, Formula IB, Formula IC, or Formula ID as shown below; and related Formula I, Formula IA, Formula IB, Formula IC, or Formula ID; Formula I, Formula IA, Formula IB, Formula IC, or Formula ID; wherein R1, R2a, R2b, R3 and R4 are as defined herein. Compounds of the Invention are useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors.

64. Substituted pyridazines as prostacyclin receptor modulators

Date: 2018-11-27 | ID: 10138210

Résumé: Cyclohexane derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

65. Non-fluorinated urethane based coatings

Date: 2018-11-27 | ID: 10138392

Résumé: A compound for imparting water repellency and optionally stain release to substrates wherein the compound is prepared by (i) reacting (a) at least one isocyanate group-containing compound selected from isocyanate, diisocyanate, polyisocyanate, or mixture thereof, and (b) at least one isocyanate-reactive compound selected from formula (Ia), (Ib), or (Ic):

66. Fitting member and replacement unit for long member

Date: 2018-11-27 | ID: 10138924

Résumé: The present invention relates to a fitting member (1) including an insertion portion (11) that fits a long member (Ia) therein and has a space through which the long member (Ia) is insertable, a movement restriction portion (14) that restricts movement that the long member (Ia) comes out of the insertion portion (11), the movement restriction portion (14) being capable of being scraped with a tool, and a guide portion (16) that guides the tool to the movement restriction portion (14) when the movement restriction portion (14) is scraped with the tool, the fitting member (1) including the movement restriction portion (14) that can be scraped with the tool to release the restriction of the movement that the long member (Ia) comes out of the insertion portion (11).

67. Automated recognition system for natural language understanding

Date: 2018-12-04 | ID: 10147419

Résumé: An interactive response system directs input to a software-based router, which is able to intelligently respond to the input by drawing on a combination of human agents, advanced recognition and expert systems. The system utilizes human intent analysts for purposes of interpreting customer input. Automated recognition subsystems are trained by coupling customer input with IA-selected intent corresponding to the input, using model-updating subsystems to develop the training information for the automated recognition subsystems.

68. Method and inverter for determining capacitance values of capacitances of an energy supply system

Date: 2018-12-04 | ID: 10148225

Résumé: A method for determining capacitance values of capacitances of a photovoltaic system including a multiphase inverter which includes an output current filter on an alternating current side thereof and is connected to a multiphase energy supply network via a switching element and is associated with at least one intermediate circuit capacitance on the direct current side thereof is provided. The method includes disconnecting the photovoltaic system from the energy supply network by opening the switching element; operating the inverter to set up an island network after the disconnecting, wherein an in-phase AC voltage is applied to at least two outputs of an inverter bridge of the multiphase inverter and a flow of current is produced between the at least one intermediate circuit capacitance and at least one filter capacitance of the output current filter; measuring currents (Ia, Ib, Ic) flowing at the outputs of the inverter bridge and at least one voltage present at one of the capacitances, and determining a capacitance value of at least one of the capacitances using the determined voltage and the measured currents (Ia, Ib, Ic).

69. Bearer management

Date: 2018-12-04 | ID: 10149205

Résumé: A method and system of bearer management signalling in a communication network comprising of transporting bearer resource request message of both the UE and RN via DeNB to managing entity of UE within EPC, as a signalling message over uplink channel referred to as Union of Resource Request (UR Request)' message. The bearer resource response message from one of the managing entity of UE or managing entities of UE and RN within EPC are transported as a signalling message to Evolved Packet Edge (EPE) via DeNB over the downlink channel referred to as Independent Admission Response (IA Response). This manages bearer setup signalling as a single loop, by transportation of UR Request signalling message over uplink and receiving one IA Response signalling message over downlink channels. EPE is a

conglomeration of network nodes comprising of UEs, RNs and all other network nodes that communicate over EPC via DeNB.

70. Indazoles and use thereof

Date: 2018-12-18 | ID: 10155752

Résumé: In one aspect, the present disclosure provides indazoles of Formula I: (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R3, R4, R5, R6, Z1, Z2, Z3, and G are defined as set forth in the specification. Further, the present disclosure also provides compounds of Formulae II and IA, and the pharmaceutically acceptable salts and solvates thereof. The present disclosure is also directed to the use of compounds of Formulae I, II, and IA, and the pharmaceutically acceptable salts and solvates thereof, to treat a disorder responsive to the blockade of sodium channels. In one embodiment, compounds of the present disclosure are especially useful for treating pain.

71. Magnetic pole position detection device of permanent magnet-type synchronous motor

Date: 2018-12-25 | ID: 10161766

Résumé: A magnetic pole position detection device of a permanent magnet-type synchronous motor detects, through a current draw-in operation, an amount of deviation between an origin of a magnetic pole position of a permanent magnet that makes up a rotor of a permanent magnet-type synchronous motor, and an origin of an output signal of a magnetic pole position sensor, and correcting the output signal of the magnetic pole position sensor on the basis of the amount of deviation, to thereby detect a true magnetic pole position. The detection device computes a phase current Ia and computes a d-axis current from the phase current Ia. The current draw-in operation is performed by causing the d-axis current to flow through armature windings of the motor, to thereby draw the rotor to the magnetic flux axial direction.

72. Selective caspase inhibitors and uses thereof

Date: 2019-01-01 | ID: 10167313

Résumé: The present invention relates to compounds of Formula I, IA, II, IIA, III, or IIIA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).

73. Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators

Date: 2019-01-08 | ID: 10174000

Résumé: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

74. Asymmetric process for the preparation of thieno-indoles derivatives

Date: 2019-01-08 | ID: 10174048

Résumé: The present invention relates to a new process for the preparation of thieno-indole derivatives of formula (Ia) or (Ib), exploiting an asymmetric synthesis for the preparation of key (8S) or (8R) 8-(halomethyl)-1-alkyl-7,8-dihydro-6H-thieno[3,2-e]indol-4-ol intermediates, and to useful intermediate compounds of such process. Thieno-indole derivatives are described and claimed in GB2344818, WO2013/149948 and WO2013/149946, which also disclose processes for their preparation. Thieno-indole enantiopure derivatives can now be advantageously prepared through a new asymmetric synthesis of the key 8-(halomethyl)-7,8-dihydro-6H-thieno[3,2-e]indol intermediates, which, avoiding the chiral resolution step, provides benefits in terms of reducing time and costs of the whole process for their preparation. The synthesis starts from the N-alkylation of 5-amino-4-halo-3-alkyl-1-benzothiophene-7-ol derivatives with enantiopure glycidyl 3-nosylate, followed by intramolecular 6-endo-tet cyclization using alkyl Grignard reagents; Mitsunobu activation of the secondary alcohol promotes internal spirocyclization, affording the 4,4a,5,6-tetrahydro-8H-cyclopropa[c]thieno[3,2-e]indol-8-one derivatives; finally, stereo-electronically controlled regioselective cyclopropane opening yields the key enantiopure 8-(halomethyl)-1-alkyl-7,8-dihydro-6H-thieno[3,2-e]indol-4-ol intermediates, which can be further derivatized following teachings disclosed in WO2013/149948 or WO2013/149946, to prepare the final thieno-indole derivatives of formula (Ia) or (Ib). Such compounds are disclosed to be alkylating compounds with cytotoxic activity, therefore useful as such in the treatment of a variety of cancers and in cell proliferative disorders, or, conjugated with different types of nucleophiles, in the preparation of Antibody Drug Conjugated derivatives.

75. Semi-solid delivery systems

Date: 2019-01-15 | ID: 10179173

Résumé: The invention provides semi-solid systems for delivering biologically active materials that include a polymer comprising 1) one or more units of formula Ia, IIa, or IIIa: (formula Ia, IIa, IIIa) and 2) one or more units comprising polycaprolactone; wherein R and Ra have any of the values defined in the application.

76. Driver circuit for an inductor coil

Date: 2019-01-15 | ID: 10181878

Résumé: Driver circuit in which a capacitor (4), in a manner controlled by a switch control device (9) which is connected downstream of a current measuring device (8), is charged to a reference voltage (Ur) by means of a charging current (Ic2), and the charged capacitor is discharged in an oscillating manner via an inductor coil (1), wherein the discharging operation is terminated when the current (Ia) through the inductor coil has passed through an entire oscillation period or several oscillation periods, wherein a first controllable switch (5) is connected in series between a first non-reactive resistor (6) and the first capacitor (4) in one of two input paths. Furthermore, a second controllable switch (7) and a fourth controllable switch (14) are connected into two output paths, and a second non-reactive resistor (13) is connected between a second connection (X2) of the inductor coil (1) and a connection for a reference potential (Um). The current measuring device (8) is connected between the fourth controllable switch (14) and the first capacitor (4).

77. Pyrimidinone derivative having autotaxin-inhibitory activity

Date: 2019-01-22 | ID: 10183949

Résumé: A compound according to any one of formula (Ia) to (Ic), or its pharmaceutically acceptable salt:

78. Thienopyrroles as histone demethylase inhibitors

Date: 2019-01-22 | ID: 10183952

Résumé: The present application relates to thienopyrrole derivatives, compounds of Formulas (I) and (Ia), wherein R, R1, R2 and R3 are as defined in the specification, pharmaceutical compositions containing such compounds and to their use in therapy. The compounds of the application can be useful for inhibiting KDM1 and the prevention and/or treatment of cancer, infectious disease, or a disease characterized by aberration of cellular energy metabolism, e.g., obesity.

79. Polyfunctional compounds

Date: 2019-01-29 | ID: 10189783

Résumé: The present invention relates to a an imide compound according to anyone of formulas Ia, Ib, Ic, or Ie wherein R1 is H or a C1-C20 optionally substituted hydrocarbon group; both R2 and R5 are a COOH group or one of R2 and R5 is a COOH group while the other substituent is H, methyl or ethyl group; R3 and R4 are independently H, or C1-C20 optionally substituted hydrocarbon group; R6 is H or a methyl group; R7 and R8 are independently H, methyl or ethyl.

80. ROR gamma (ROR) modulators

Date: 2019-02-05 | ID: 10196350

Résumé: The present application relates to compounds according to (Formula IA) or (Formula IB): The compounds can be used as inhibitors of ROR and are useful for the treatment of ROR mediated diseases.

81. Method for analyzing signals providing instantaneous frequencies and sliding Fourier transforms, and device for analyzing signals

Date: 2019-02-12 | ID: 10204076

Résumé: The present invention is relative to a method for analyzing an signal (INS), representative of a wave that propagates in a physical medium, providing characteristic parameters of said signal, said method being implemented on a computing platform (CP), requiring only fixed point computations, and with a reduced number of multiplications. Parameters that are provided can be one or several of the following: instantaneous phase (IP), instantaneous amplitude (IA), instantaneous frequency (IF), Sliding Fourier Transform (STFT).

82. Sustained release formulation and tablets prepared therefrom

Date: 2019-02-19 | ID: 10207002

Résumé: Disclosed are formulations and tablets made therefrom comprising the compound of Formula IA or Formula IB which have sustained-release properties, and the dispersion containing the compounds of Formula IA or IB which facilitates such sustained release: Formula IA, Formula IB.

83. Macrocycles as factor XIa inhibitors

Date: 2019-02-19 | ID: 10208068

Résumé: The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

84. Tire member manufacturing method and tire manufacturing method

Date: 2019-02-19 | ID: 10208137

Résumé: A first tire member manufacturing method includes an operation in which a pre-coagulation rubber latex containing carbon black, for which a ratio of specific surface area as determined by nitrogen adsorption N2SA (in units of m2/g) to an amount of iodine absorption IA (in units of mg/g) is not less than 1.00, is coagulated to obtain a coagulum; an operation in which a compound according to Formula (I), below, is added to the water-containing coagulum; and an operation in which the compound according to Formula (I),

below, is dispersed within the coagulum.In Formula (I), R1 and R2 each indicates a hydrogen atom, an alkyl group having 1 to 20 carbons, an alkenyl group having 1 to 20 carbons, or an alkynyl group having 1 to 20 carbons, R1 and R2 may be the same or different, and M+ indicates sodium ion, potassium ion, or lithium ion.

85. Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto

Date: 2019-02-26 | ID: 10214518

Résumé: Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

86. Phosphatidylinositol 3-kinase inhibitors

Date: 2019-02-26 | ID: 10214519

Résumé: The present application provides the compounds of formula I or IA

87. Group B Streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof

Date: 2019-03-12 | ID: 10226525

Résumé: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein

the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

88. Diagnosis and treatment of invasive aspergillosis

Date: 2019-03-12 | ID: 10227629

Résumé: Methods for diagnosing, treating, and monitoring the treatment of invasive aspergillosis (IA) are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having IA.

89. Harmonic current compensator and air-conditioning system

Date: 2019-04-02 | ID: 10250037

Résumé: A harmonic current compensator is connected in parallel with a harmonic generating load to a system power supply and supplies a compensation current Ia to limit a harmonic component contained in a load current IL to be input from the system power supply to the harmonic generating load. The harmonic current compensator includes: a load current detector that detects the load current IL; a compensation current detector that detects the supplied compensation current Ia; a control amount computing portion that computes a control amount of the compensation current Ia based on the harmonic component contained in the load current IL detected by the load current detector and the compensation current Ia detected by the compensation current detector; and a limiter that limits an upper limit of the compensation current Ia.

90. System and method for intelligent assistant service

Date: 2019-04-02 | ID: 10251115

Résumé: Artificial intelligence-based, intelligent agent (IA) services may include an IA server assisting users of a wireless network in various communication scenarios (e.g., calls, texts, chats, etc.). A user may specify rules for managing communications directed to a User Equipment (UE) of the user. Examples of such rules may include intercepting an incoming call to the user, managing the call based on whether the user is available, determining a reason for an incoming call and notifying the user about the reason, inviting the user to join the call, adding other users to the call, recording portions of the call, providing requested information, taking notes, scheduling meetings, and providing other assistant-type services, etc. The IA services may also include monitoring, interpreting, and responding to information that is sent to, or by, the user, during a communication, in addition to implementing Machine Learning procedures for self-improvement.

91. Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging

Date: 2019-04-09 | ID: 10253020

Résumé: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where:

92. Liquid crystal material

Date: 2019-04-16 | ID: 10260001

Résumé: The present application relates to a liquid-crystalline material which comprises at least one dye compound and at least one compound of a formula (IA) or (IB). The liquid-crystalline material is suitable for use in optical switching devices, in particular in devices for the homogeneous regulation of the passage of light through an area.

93. Pharmaceutical composition comprising nanoparticles, preparation and uses thereof

Date: 2019-04-23 | ID: 10265406

Résumé: The present application relates to a pharmaceutical composition comprising biocompatible nanoparticles or nanoparticles aggregates which allows the appropriate delivery of said biocompatible nanoparticles or nanoparticles aggregates to a target site in a subject in need thereof. The composition indeed allows an accumulation of the biocompatible nanoparticles or nanoparticles aggregates it comprises into the targeted tissue of the subject of at least 4 milligram (mg) nanoparticles or nanoparticles aggregates per gram (g) of targeted tissue when at least 0.1 g of the pharmaceutical composition per kilogram (kg) of body weight is injected intravenously (IV) or intraarterially (IA) into said subject.

94. Process for the preparation of thietane derivatives

Date: 2019-04-23 | ID: 10266524

Résumé: The present invention relates to processes for the preparation of thietane derivatives of the formula IA and thietane derivatives of the formula IB wherein R1, R2, A1, A2, A3, A4, B, and n are as defined in the claims. The invention also relates to intermediates useful in the processes, as well as the compounds of formula IA and IB and their use as pesticides.

95. Polymorph of Syk inhibitors

Date: 2019-04-23 | ID: 10266539

Résumé: Polymorphs of a bis-mesylate salt of a compound of Formula I: or a hydrate thereof, are provided. The bis-mesylate salt may also be depicted as a compound of Formula IA: Provided herein are also

compositions thereof, methods for their preparation and methods for such polymorphs.

96. BCL-3 inhibitors

Date: 2019-04-30 | ID: 10273218

Résumé: The present application relates to compounds of any one of Formulae I, Ia, Ib, Ic, Id, Ie, and If. Compounds of Formula (I) have the structure:

97. Macrocyclic factor XIa inhibitors bearing heterocyclic groups

Date: 2019-04-30 | ID: 10273236

Résumé: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

98. Substituted dihydropyrrolopyrazole derivative

Date: 2019-04-30 | ID: 10273252

Résumé: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.

99. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors

Date: 2019-05-07 | ID: 10280176

Résumé: Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

100. Methods for the synthesis of functionalized nucleic acids

Date: 2019-05-07 | ID: 10280192

Résumé: The present application, among other things, provides technologies, e.g., reagents, methods, etc. for preparing oligonucleotides comprising phosphorothiotriesters linkages. In some embodiments, provided

methods comprise reacting an H-phosphonate of structure Ia or Ib with a silylating reagent to provide a silyloxyphosphonate, and reacting the silyloxyphosphonate with a thiosulfonate reagent of structure IIa or IIb to provide an oligonucleotide of structure IIIa or IIIb. In some embodiments, provided methods comprise reacting an H-phosphonate of structure Ic with a silylating reagent to provide a silyloxyphosphonate, reacting the silyloxyphosphonate with a bis(thiosulfonate) reagent of structure IVc to provide a phosphorothiotriester comprising a thiosulfonate group of structure Vc, and then reacting the phosphorothiotriester comprising a thiosulfonate group of structure Vc with a nucleophile of structure VIc to provide an oligonucleotide of structure IIIc. In some embodiments, the present application provides a thiosulfonate reagent of structure IIa:

101. Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers

Date: 2018-06-19 | ID: 10000487

Résumé: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula IA or Formula IB, as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof. For Formula IA and Formula IB compounds A1, A2, A3, A4, W1, W2, Y, X, R1, R2, R3, R4a, R4b, R5a, R5b, R6, R7, R8, R9, R9a, R9b, R10 and subscript n are as defined in the specification. The inventive Formula IA and Formula IB compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

102. Flame retarding agent, flame-retardant aqueous resin composition and flame-retardant urethane resin composition containing said flame-retarding agent, and use therefor

Date: 2018-06-19 | ID: 10000625

Résumé: The present invention relates to a flame-retarding agent comprising a phosphoramidate compound represented by Formula (I): wherein R1 and R2 are each independently C1-3 alkyl, R11 and R12 are each independently C1-3 alkylene, R13 is C1-6 alkylene, B1 is hydrogen or C1-6 alkyl, and A is hydrogen or an organic group represented by Formula (Ia): wherein R3 and R4 are each independently C1-3 alkyl, R14 and R15 are each independently C1-3 alkylene, and B2 is hydrogen or C1-6 alkyl, wherein when B1 is C1-6 alkyl, and A is hydrogen, B1 and R13-A, taken together with nitrogen to which they are attached, may form a non-aromatic nitrogen-containing heterocycle, and wherein when B1 is C1-6 alkyl, A is an organic group represented by Formula (Ia), and B2 is C1-6 alkyl, B1 and B2, taken together with nitrogen to which they are attached and with R13, may form a non-aromatic nitrogen-containing heterocycle.

103. Method for predicting failure of a light-emitting diode

Date: 2018-06-19 | ID: 10001522

Résumé: A method for predicting failure of a light-emitting diode, includes applying a test potential difference across the terminals of the light-emitting diode lower than its minimum drive potential difference, the test potential difference having the same sign as the minimum drive potential difference; measuring the current Ic flowing through the light-emitting diode during the application of the test potential difference; and generating an alarm signal when the measured current Ic exceeds an alarm threshold Ia.

104. Photopolymer formulation for production of holographic media comprising borates with low TG

Date: 2018-06-19 | ID: 10001703

Résumé: The invention relates to a photopolymer formulation comprising a component reactive toward isocyanates, a polyisocyanate component, a writing monomer and a photoinitiator containing at least one dye and a coinitiator, characterized in that the coinitiator contains at least one substance of the formula (Ia)The invention further provides a process for preparing the specific coinitiators and the coinitiators obtainable by this process, and additionally a process for producing a holographic medium using the specific coinitiators, and a holographic medium obtainable using the inventive photopolymer formulation. The invention further relates to a laminate structure comprising an inventive holographic medium and likewise specific borates suitable as coinitiators.

105. Power conversion device

Date: 2018-06-19 | ID: 10003277

Résumé: A power converter including a compressor as a load includes a compensation current output (80) allowing compensation current (Ic), which compensates for leakage current (Ia), to flow. A controller (50) receives a detection signal from a rotational speed sensor (55) which senses the rotational speed of the compressor (CM). When the rotational speed has increased to a set rotational speed at which the leakage current (Ia) is lower than or equal to its limiting value (Lmax) (e.g., the limiting value specified under the Electrical Appliances and Materials Safety Act or by the IEC) in a state where the compensation current output (80) is off, the compensation current output (80) is switched from an on state to an off state. This may reduce the leakage current from the compressor with low power loss.

106. Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof

Date: 2018-06-26 | ID: 10004750

Résumé: The present invention provides an acid addition salt or a sodium salt of a compound represented by the formula (IA): or their hydrate or a stable crystalline solid thereof. The salt or the crystalline solid is extremely useful as an active ingredient for the production of a pharmaceutical product.

107. Anticancer agent

Date: 2018-06-26 | ID: 10005752

Résumé: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.

108. Device, system and method for illuminating a target area

Date: 2018-07-03 | ID: 10011356

Résumé: An illumination device (6) comprising a light source (8) producing a first cone of light (10) and a deflection unit (12) for the beam-shaping conversion of the first cone of light (10) into a second cone of light (14a,b) and to emit the latter towards the target area (4a,b), the deflection unit (12) can be varied in order to vary the form (Fa,b) and/or the intensity distribution (Ia,b) in the second cone of light.An illumination system (2) contains the illumination device (6) and the target area (4a,b).The illumination device (6) or the illumination system (2) is used to illuminate a surface of an interior of a vehicle as target area (4a,b).

109. Adsorbent for desulfurization of gasoline and method for desulfurization of gasoline

Date: 2018-07-03 | ID: 10011779

Résumé: The present invention provides an adsorbent and a method for desulfurization of gasoline. The adsorbent is obtained by loading active metal component on a composite carrier comprising zeolite and active carbon subjected to alkali treatment respectively, the active metal is selected from one or more elements of IA, IIA, VIII, IB, IIB and VIB groups in the periodic table. This method uses the adsorbent to conduct gasoline adsorption desulfurization, which especially cuts the gasoline into a light and a heavy gasoline fraction firstly, then the light fraction is subjected to adsorption desulfurization using the adsorbent, and the heavy fraction is subjected to selective hydrodesulfurization, a cutting temperature of the light and the heavy gasoline fraction is 70-110° C. The adsorbent has a large sulfur adsorption, a long service life, and simply to be regenerated; the method can realize deep desulfurization of gasoline, and has a less octane number loss.

110. Compounds, compositions, and methods for increasing CFTR activity

Date: 2018-07-10 | ID: 10017503

Résumé: The disclosure encompasses compounds having e.g., Formula (Ia) or (Ib), compositions thereof, and methods of modulating CFTR activity. The disclosure also encompasses methods of treating a condition associated with CFTR activity or condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a compound of Formula (I) or (Ib).

111. Substituted 5-hydroxy-2,3-diphenylpentanonitrile derivatives, processes for their preparation and their use as herbicides and/or plant growth regulators

Date: 2018-07-17 | ID: 10021877

Résumé: Primarily, the present invention relates to the use of substances of the formula (I) as herbicides, in particular for controlling broad-leaved weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influencing the growth of crops of useful plants. The invention furthermore relates to the novel herbicidal substances of the formulae (Ib) and (Ia). The present invention also relates to corresponding compositions comprising one or more of the herbicides of the formula (I) and further agrochemically active substances, and also to plant growth-regulating or herbicidal compositions comprising one or more of these compounds. Moreover, the present invention relates to processes for preparing the compounds of the formula (I).

112. Spirocyclic morphinans and use thereof

Date: 2018-07-24 | ID: 10030021

Résumé: In one aspect, the invention provides compounds of Formula I: (I) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, Y, Za are defined as set forth in the disclosure. The invention also provides compounds of any one of Formulae II to VII, IA to IC, and IIA to IIC, and pharmaceutically acceptable salts and solvates thereof. Other aspects of the invention include the use of compounds of Formulae I to VII, IA to IC, and IIA to IIC, and pharmaceutically acceptable salts and solvates thereof for the treatment of disorders responsive to modulation of one or more opioid receptors. In certain embodiments, the Compounds of the Invention are useful for treating pain.

113. Diagnosis and treatment of invasive aspergillosis

Date: 2018-07-24 | ID: 10031125

Résumé: Methods for diagnosing, treating, and monitoring the treatment of invasive aspergillosis (IA) are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having IA.

114. Pressure detecting device and touch panel

Date: 2018-07-24 | ID: 10031606

Résumé: The invention provides a pressure detecting device containing a pressurized member having a contact surface that is subjected to pressure due to contact with a pressurizing means; and a piezoelectric member that is arranged facing the pressurized member and that includes a polymeric piezoelectric material having a piezoelectric constant d14 of 1 pm/V or more as measured by a displacement method at 25° C., and a ratio IEb/IEa between a product IEb of a cross-sectional secondary moment Ib and a Young's modulus Eb of the pressurized member, and a product IEa of a cross-sectional secondary moment Ia and a Young's modulus Ea of the piezoelectric member, is in a range of from 102 to 1010.

115. Sulfide solid electrolyte material, battery, and producing method for sulfide solid electrolyte material

Date: 2018-07-24 | ID: 10033065

Résumé: A main object of the present invention is to provide a sulfide solid electrolyte material having favorable ion conductivity and low reduction potential. The present invention solves the above-mentioned problem by providing a sulfide solid electrolyte material including an M1 element (such as a Li element), an M2 element (such as a Ge element, a Si element and a P element) and a S element, wherein the material has a peak at a position of 2=29.58°±0.50° in X-ray diffraction measurement using a CuK line; and when a diffraction intensity at the peak of 2=29.58°±0.50° is regarded as IA and a diffraction intensity at a peak of 2=27.33°±0.50° is regarded as IB, a value of IB/IA is less than 0.50, and M2 contains at least P and Si.

116. Flame-retardant expandable polymers

Date: 2018-07-31 | ID: 10035892

Résumé: The present relates to flame-retardant expandable polymers and to polymer foams and to the use thereof. These flame-retardant expandable polymers and polymer foams can be contained in one or several pressurized containers. According to the present, at least one of the following phosphorus compounds is used as a flame retardant: phosphorus compound according to formula (Ia): (Ia) 10-hydroxy-9, 10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide (DOPO-OH); or the salts thereof according to formula (Ib): (Ib) (DOPO-OR); or the ring-opened hydrolysates thereof according to formula (Ic): (Ic).

117. Inhibitors of influenza viruses replication

Date: 2018-08-07 | ID: 10039762

Résumé: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of

reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

118. Process for producing a fuel cell electrode catalyst, fuel cell electrode catalyst and use thereof

Date: 2018-08-07 | ID: 10044045

Résumé: Provided is a process for producing a fuel cell electrode catalyst with high catalytic activity that is alternative to a noble metal catalyst, through a heat treatment at a relatively low temperature. A process for producing a fuel cell electrode catalyst includes a step (I) of obtaining a catalyst precursor, including a step (Ia) of mixing at least a metal compound (1), a nitrogen-containing organic compound (2), and a fluorine-containing compound (3), and a step (II) of heat-treating the catalyst precursor at a temperature of 500 to 1300° C. to obtain an electrode catalyst, a portion or the entirety of the metal compound (1) being a compound containing an atom of a metal element M1 selected from the group consisting of iron, cobalt, chromium, nickel, copper, zinc, titanium, niobium and zirconium, and at least one of the compounds (1), (2) and (3) containing an oxygen atom.

119. Frame transmission system and method of interference alignment and controlling in multi-cell random access network

Date: 2018-08-07 | ID: 10045240

Résumé: Provided is a frame transmission method of interference alignment (IA) and controlling, the method including calculating a channel matrix of a basic service set (BSS) by measuring channel information between an access point and a user terminal, performing singular value decomposition (SVD) based on the calculated channel matrix, selecting a beamforming vector in consideration of an interference amount associated with another access point based on the SVD performed by the channel matrix, and calculating a leakage interference (LIF) value based on the selected beamforming vector.

120. Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Date: 2018-08-14 | ID: 10047083

Résumé: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

121. Liquid-crystalline medium

Date: 2018-08-14 | ID: 10047292

Résumé: The invention relates to a liquid-crystalline medium, characterized in that it comprises one or more compounds of the formula IA, and one or more compounds of the formula IB, in which RA, RB, XA, XB and Y1-13 have the meanings indicated in claim 1, and to the use thereof for electro-optical purposes, in particular for shutter glasses, 3D applications, in TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, PS-FFS and PS-VA-IPS displays.

122. Network node and method for enabling interference alignment of transmissions to user equipments

Date: 2018-08-14 | ID: 10050734

Résumé: A method performed by a network node for enabling Interference Alignment, IA, of transmissions to user equipments is provided. The network node receives signal strength values associated with more than one network node for the user equipments, wherein each signal strength value is associated with one network node. Then, the network node schedules a first group of the user equipments on radio transmission resources that are orthogonal to radio transmission resources of at least one other group of the user equipments when an IA gain value for each user equipment in the first group passes a threshold level. The IA gain value is determined by the network node based on the received signal strength values. The network node may then enable IA of transmissions to the scheduled first group of user equipments from at least two network nodes capable of performing IA of transmissions.

123. Compounds and their use as BACE inhibitors

Date: 2018-08-21 | ID: 10053453

Résumé: The present application relates to compounds of formula (I), (Ia), or (Ib) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing A-related pathologies such as Down's syndrome, -amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (mild cognitive impairment), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia, including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.

124. Process for preparing chiral dipeptidyl peptidase-IV inhibitors

Date: 2018-08-21 | ID: 10053466

Résumé: A process for preparing a compound of structural Formula Ia:

125. Imidazo[1,2-]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto

Date: 2018-08-28 | ID: 10058549

Résumé: rmidazo[1,2-]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia, dyssomnia, parasomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic- related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to methods for the treatment of 5-HT2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.

126. Imidazolidinedione derivatives

Date: 2018-08-28 | ID: 10058551

Résumé: The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or

epilepsy.

127. Sialon sintered body and cutting insert

Date: 2018-08-28 | ID: 10058925

Résumé: A sialon sintered body and a cutting insert each having thermal shock resistance and VB wear resistance. The sialon sintered body and the cutting insert contain -sialon and 21R-sialon and exhibit an X-ray diffraction peak intensity ratio [(I21R/IA)×100] of 5% or greater and smaller than 30%, wherein IA represents the sum of the peak intensities of the sialon species, and I21R represents the peak intensity of 21R-sialon, the ratio being calculated from the peak intensities of the sialon species obtained by using X-ray diffractometry.

128. Heterogeneous catalysts for the transesterification of aromatic alcohols; and methods of making and use thereof

Date: 2018-08-28 | ID: 10059652

Résumé: Disclosed herein are new mixed metal oxide catalysts suitable as heterogeneous catalysts for catalyzing the transesterification process of aromatic alcohols with a dialkyl carbonate to form aromatic carbonates. The heterogeneous catalyst comprises a combination of two, three, four, or more oxides of Mo, V, Nb, Ce, Cu, Sn, or an element selected from Group IA or Group IIA of the periodic table.

129. Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof

Date: 2018-09-04 | ID: 10064848

Résumé: Compounds for the preparation of pyridone derivatives are provided. In particular, compounds of formula (IA) are provided, wherein the variable groups are as defined in the specification. The compounds of formula (IA) can be used as intermediates in the preparation of pyridone derivatives useful as mitogen-activated protein kinase kinase (MEK) inhibitors and therapeutic agents for treating cancer.

130. Substituted imidazo[4,5-c]pyridines as SSAO inhibitors

Date: 2018-09-04 | ID: 10065954

Résumé: Specific compounds of formula (Ia): and pharmaceutically acceptable salts thereof. Pharmaceutical compositions of the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof. A method for inhibiting tumor growth in a subject that includes administering to the subject an effective amount of a compound selected from the specific compounds of formula (Ia) and pharmaceutically acceptable salts

thereof. A method for modulating semicarbazide-sensitive amine oxidase activity in a subject that includes administering to the subject an effective amount of a compound selected from the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof.

131. Pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors

Date: 2018-09-04 | ID: 10065964

Résumé: The present invention relates to compounds of formula (Ia), (Ib) or (Ic): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma, COPD, allergic rhinitis, chronic sinusitis, atopic dermatitis, psoriasis, rosacea, alopecia, allergic conjunctivitis and dry eye disease.

132. Alkyd resin compositions

Date: 2018-09-04 | ID: 10066053

Résumé: The present invention relates to an alkyd resin composition comprising a. 1-60 wt % of an imide compound according to anyone of formulas Ia, Ib, Ic, Id or Ie wherein R1 is H or a C1-C20 optionally substituted hydrocarbon group; R2 and R5 are independently H, or a C1-C20 hydrocarbon group; R3 and R4 are independently H, or a C1-C20 hydrocarbon group; R6 is H or a methyl group; R7 and R8 are independently H, methyl or ethyl; b. 10-40 wt % of an alcohol having a number average hydroxy functionality 2.0; c. 30-70 wt % of fatty acids or vegetable oils; d. 0-50 wt % of a mono and/or polyfunctional compound capable of esterification, which compound is different from the compounds used in a, b and c; wherein the wt % is determined relative to the total of weight of compounds a, b, c and d.

133. Polymeric ion conductor with improved thermal characteristics

Date: 2018-09-04 | ID: 10066068

Résumé: The present disclosure provides polymers comprising at least one repeat unit represented by any one of structural formulas (IA)-(IE) disclosed herein, for example: Values for the variables are as disclosed herein. The polymers provided can be employed as ion conductors, for example in fuel cells, and have improved thermal characteristics.

134. Intellectual asset family creation

Date: 2018-09-04 | ID: 10068300

Résumé: An example embodiment includes a method for creating a family of related intellectual asset (IA) records. The method may include obtaining IA data for a current filing. The method may include creating an

IA record for the current filing. The method may include obtaining IA data for one or more related filings. The current filing and the one or more related filings belong to a family of intellectual assets. The method may also include preparing for creation of a plurality of IA records for the one or more related filings based on the IA data for the current filing and the IA data for the one or more related filings. The method may further include creating a plurality of new IA records for the one or more related filings.

135. Therapeutic compounds

Date: 2018-09-11 | ID: 10071985

Résumé: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

136. Compounds and methods for the treatment of cystic fibrosis

Date: 2018-09-11 | ID: 10072017

Résumé: The invention relates to a compound of Formula I or IA compositions comprising compounds of Formula I or IA, and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof:

137. Diarylethene compounds and uses thereof

Date: 2018-09-11 | ID: 10072023

Résumé: A compound according to Formula IA and IB, reversibly convertible under photochromic and electrochromic conditions between a ring-open isomer A and a ring-closed isomer B is provided. For substitutent groups, Z is N, O or S; each R1 is independently selected from the group consisting of H, or halo; each R2 is independently selected from the group consisting of H, halo, a polymer backbone, alkyl or aryl; or, when both R2 together form CHCH and form part of a polymer backbone; each R3 is independently selected from the group consisting of H, halo, alkyl, alkoxy, thioalkyl or aryl; each R4 is aryl; and each R5 is independently selected from the group consisting of H, halo, alkyl, alkoxy, thioalkyl or aryl.

138. Non-ionic compound, resin, resist composition and method for producing resist pattern

Date: 2018-09-11 | ID: 10073343

Résumé: A compound which is non-ionic compound, the compound has a group represented by formula (Ia): wherein R2 represents a group having a C3 to C18 alicyclic hydrocarbon group where a methylene group may be replaced by an oxygen atom or a carbonyl group, Rf1 and Rf2 each independently represent a C1 to C4 perfluoroalkyl group, and * represents a binding site.

139. Tricyclic prodrugs

Date: 2018-09-18 | ID: 10077246

Résumé: Prodrugs (I) and (Ia) of galiellactone, and derivatives thereof, are provided by reacting the parent compound, e.g. galiellactone, with a thiol. Such drugs may be administered orally to treat cancer and other proliferative diseases.

140. Read-through compound prodrugs suppressing premature nonsense mutations

Date: 2018-09-18 | ID: 10077260

Résumé: Premature termination codon readthrough prodrug compounds, compositions thereof, and methods of making and using the same are provided. In certain embodiments, the compounds are of Formula Ia or a pharmaceutically acceptable salt, solvate, polymorph, hydrate, ester, isomer, stereoisomer, or tautomer thereof, wherein R, A and W are as described herein.

141. Temperature detection apparatus and rotation angle detection apparatus

Date: 2018-09-18 | ID: 10078018

Résumé: A temperature detection apparatus and a rotation angle detection apparatus are provided that allow a temperature of a resolver to be calculated in real time. A rotation angle detection apparatus (10) (temperature detection apparatus) includes a resolver (20) with an excitation coil and output coils wound thereon, the excitation coil being subjected to an excitation voltage (VA) and the output coil outputting voltage signals (VB, VC) corresponding to the excitation voltage (VA), and a temperature calculation circuit (sensor microcomputer (32)) that detects a phase of the excitation voltage (VA) and that detects a phase of an excitation current (IA). The temperature calculation circuit (sensor microcomputer (32)) calculates a temperature of the resolver (20) based on a phase difference between the excitation voltage (VA) and the excitation current (IA).

142. Dither current power supply control method and dither current power supply control apparatus

Date: 2018-09-18 | ID: 10079087

Résumé: In the dither current power supply control method, in order to prevent occurrence of a difference between the target average current and the detected average current, which is caused when a medium current (I0) between a dither large current (I2) and a dither small current (I1) and a waveform average (Ia) of the dither current are different from each other depending on a response time difference (ab) between a rise time (b) and a fall time (a) of the dither current, negative feedback control is carried out by using a command

medium current corresponding to the target average current corrected by a correction parameter based on experimentally measured data, thereby suppressing occurrence of a transient fluctuation error by the negative feedback control, so that a highly precise and stable load current is acquired.

143. Substituted benzoxazine and related compounds

Date: 2018-10-02 | ID: 10087151

Résumé: The present invention relates to compounds including but not limited to of any one of formulas Ia, Ib, IIa, IIb, IIIa, IIIb, and IV to VI, VIIa, VIIb, VIIIa, VIIIb and VIIIc as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.

144. Inference alignment (IA) method for uplink in wireless local area network (WLAN) system, access point (AP) and user terminal for performing the same

Date: 2018-10-02 | ID: 10091794

Résumé: An interference alignment (AI) method for an uplink in a wireless local area network (WLAN) system, an access point (AP) and a user terminal for performing the same, and the AP that may select an interference space, broadcast information on the selected interference space, select a user terminal to be assigned a data transmission opportunity based on leakage of interference (LIF) information received from at least one user terminal, receive data from the user terminal, and decode the data using a minimum square error (MMSE) based receiving filter.

145. Process for the preparation of substituted phenoxyphenyl ketones

Date: 2018-10-09 | ID: 10093634

Résumé: The present invention relates to a process for the preparation of the ketone compounds (IA) and their use as intermediates for the preparation of triazole fungicides.

146. Hepatic stellate cell precursors and methods of isolating same

Date: 2018-10-09 | ID: 10093895

Résumé: The present invention relates to precursor cells to hepatic stellate cells, compositions comprising same and methods of isolating same. The surface antigenic profile of the precursors is MHC class Ia negative, ICAM-1+, VCAM-1+, 3-integrin+. In addition to expression of these surface markers, the cells also express the intracellular markers desmin, vimentin, smooth muscle -actin, nestin, hepatocyte growth factor, stromal derived factor-1 and Hlx homeobox transcriptional factor.

147. Resin, resist composition and method for producing resist pattern

Date: 2018-10-16 | ID: 10101657

Résumé: A resist composition contains: a resin having an acid-labile group, a resin having a structural unit represented by formula (I), an acid generator, and a solvent; wherein Ri41 represents a hydrogen atom or a methyl group, Ri42 represents a C1 to C10 hydrocarbon group that may be substituted with a hydroxy group, a C2 to C7 acyl group or a hydrogen atom, Ri43 in each occurrence independently represents a C1 to C6 alkyl group or a C1 to C6 alkoxy group, p represents an integer of 0 to 4, Z represents a divalent C3 to C20 hydrocarbon group having a group represented by formula (Ia), and a methylene group contained in the hydrocarbon group may be replaced by an oxygen atom, a sulfur atom or a carbonyl group, *[(CH2)wO]r (Ia): wherein w and r each independently represents an integer of 1 to 10, and * represent a bonding position.

148. Mobile terminal and controlling method thereof

Date: 2018-10-16 | ID: 10104208

Résumé: Disclosed are a mobile terminal for providing an intelligent agent (IA) service and controlling method thereof. The mobile terminal includes a display unit, a camera, a sensing unit comprising a microphone configured to sense a surrounding voice of the mobile terminal, an angle sensor configured sense an angle of the mobile terminal, and a location sensor configured to sense a location of the mobile terminal, a communication unit configured to transmit/receive data with a server configured to store a context information of a user, and a controller, if a trigger signal including a preset voice signal is sensed through the microphone, activating an intelligent agent (IA), the controller, if a preset input signal is sensed in a state that the IA is activated, activating the camera.

149. Thermal spray material, thermal spray coating and thermal spray coated article

Date: 2018-10-23 | ID: 10106466

Résumé: This invention provides a thermal spray material capable of forming a thermal spray coating excellent in plasma erosion resistance as well as in properties such as porosity and hardness. The thermal spray material comprises a rare earth element oxyhalide (RE-OX) which comprises a rare earth element (RE), oxygen (O) and a halogen atom (X) as its elemental constituents. The thermal spray material has an X-ray diffraction pattern that shows a main peak intensity IA corresponding to the rare earth element oxyhalide, a main peak intensity IB corresponding to a rare earth element oxide and a main peak intensity IC corresponding to a rare earth element halide, satisfying a relationship [(IB+IC)/IA]<0.02.

150. Monothiol mucolytic agents

Date: 2018-10-23 | ID: 10106551

Résumé: Provided are mucolytic agents represented by formula (Ia)-(Id): where the structural variables R1,

R2, R5 and R6 are as defined herein. Also provided are a variety of methods of treatment which take advantage of the mucolytic properties of the compounds represented by formula (Ia)-(Id).

151. Mixed cathode material with high energy density

Date: 2018-10-23 | ID: 10109846

Résumé: The present invention relates to an electrochemical cell comprising an anode of a Group IA metal and a cathode of a composite material prepared from a first active cathode material of a transition metal phosphate mixed or added to a second active cathode material of a carbonaceous material. The cathode material of the present invention provides increased rate pulse performance compared to carbon monofluoride cathode material. In addition, the cathode material of the present invention is chemically stable which makes it particularly useful for applications that require increased rate capability in extreme environmental conditions such as those found in oil and gas exploration.

152. P2X7 modulators and methods of use

Date: 2018-10-30 | ID: 10112937

Résumé: The present invention is directed to compounds of Formulas (I, Ia, IIa and IIb). The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, Ia, IIa and IIb). Methods of making and using the compounds of Formulas (I, Ia, IIa and IIb) are also within the scope of the invention.

153. Benzodiazepine dimers, conjugates thereof, and methods of making and using

Date: 2018-10-30 | ID: 10112975

Résumé: Benzodiazepine dimers having a structure represented by wherein R1 is wherein the variables in formulae (I), (Ia), and (Ib) are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used in an antibody-drug conjugate (ADC).

154. Adeno-associated virus vectors for treatment of glycogen storage disease

Date: 2018-10-30 | ID: 10113183

Résumé: The present disclosure describes improved adeno-associated virus (AAV) vectors for gene therapy applications in the treatment of glycogen storage disease, particularly glycogen storage disease type Ia (GSD-Ia). Described are recombinant nucleic acid molecules, vectors and recombinant AAV that include a G6PC promoter/enhancer, a synthetic intron, a G6PC coding sequence (such as a wild-type or codon-optimized G6PC coding sequence), and stuffer nucleic acid sequence situated between the G6PC promoter/enhancer and the intron, as well as between the intron and the G6PC coding sequence. The recombinant AAVs disclosed herein exhibit highly efficient liver transduction and are capable of correcting

metabolic abnormalities in an animal model of GSD-Ia.

155. Apparatus, system and method for initiation of buried explosives

Date: 2018-10-30 | ID: 10113843

Résumé: An initiator apparatus (IA) for blasting, the apparatus including: a magnetic receiver for receiving a magnetic communication signal through the ground by detection of a magnetic field; a controller, in electrical communication with the magnetic receiver, for processing the magnetic communication signal to determine a command for blasting; and a light source in electrical communication with the controller for generating a light beam to initiate a light-sensitive explosive (LSE) in accordance with the command.

156. Arginase inhibitors and methods of use

Date: 2018-11-06 | ID: 10118936

Résumé: The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.

157. Stable 2,3,3,3-tetrafluoropropene composition

Date: 2018-11-06 | ID: 10119055

Résumé: A stable composition (CS) including at least x wt.-% 2,3,3,3-tetrafluoropropene (99.8 ÿ x<100), at most y wt.-% unsaturated compound(s) (Ia) (0<y ÿ 0.2) selected from among 3,3,3-trifluoropropene (HFO-1243zf) and the positional isomers of 2,3,3,3-tetrafluoropropene, such as 1,3,3,3-tetrafluoropropene (isomers Z and E) and 1,1,2,3-tetrafluoropropene, and, optionally, at most 500 ppm of 3,3,3-trifluoropropyne and/or at most 200 ppm 1,1,1,2,3-pentafluoropropene (HFO-1225ye).

158. Sulfide solid electrolyte material, battery, and method for producing sulfide solid electrolyte material

Date: 2018-11-13 | ID: 10128532

Résumé: Sulfide solid electrolyte material with favorable ion conductivity, wherein charge and discharge efficiency is inhibited from decreasing. Solves problem by providing a sulfide solid electrolyte material including a Li element, Si element, P element, S element and O element, having peak at position of 2=29.58°±0.50° in X-ray diffraction measurement using CuK ray, wherein sulfide solid electrolyte material does not have peak at position of 2=27.33°±0.50° in X-ray diffraction measurement using CuK ray, or in case of having peak at position of 2=27.33°±0.50°, value of IB/IA is 1 or less when diffraction intensity at peak of

2=29.58°±0.50° is regarded as IA and diffraction intensity at peak of 2=27.33°±0.50° is regarded as IB; and wherein molar fraction of O element to total of S element and O element is larger than 0.2.

159. Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals

Date: 2018-11-20 | ID: 10130635

Résumé: The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals. In particular, the present invention concerns enantiomerically pure optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives represented by formula (IA) and (IB), processes for preparing the alcohol derivatives and their use in preparing pharmaceuticals.

160. Heterodimers of glutamic acid

Date: 2018-11-20 | ID: 10131627

Résumé: Compounds of Formula (Ia) wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C6 substituted or unsubstituted alkyl or NRR,

161. 5 phosphate mimics

Date: 2018-11-20 | ID: 10131908

Résumé: The present invention provides nucleosides and oligonucleotides comprising a 5 phosphate mimics of formula (IVc) or (Vc), One aspect of the present invention relates to modified nucleosides and oligonucleotides comprising such dinucleotide of formula (Ia). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.

162. Method and apparatus for performing wireless communication based on heterogeneous interference alignment (IA) scheme in wireless local area network (WLAN)

Date: 2018-11-20 | ID: 10136348

Résumé: Provided is a method and apparatus for performing a wireless communication based on a heterogeneous interference alignment (IA) scheme for a downlink multi-user multiple-input and multiple-output (DL MU-MIMO) communication in a wireless local area network (WLAN), and a wireless communication method employing a hybrid scheme that may include storing maximum throughputs of IA

schemes, measuring an environment of a wireless network, calculating predicted throughputs of the IA schemes based on the measured environment of the wireless network, selecting an IA scheme from among the IA schemes based on the predicted throughputs, and communicating with a user terminal based on the selected IA scheme.

163. Benzomorphan analogs and the use thereof

Date: 2018-11-27 | ID: 10138207

Résumé: The present invention is directed to Benzomorphan Analog compounds of the Formula I, Formula IA, Formula IB, Formula IC, or Formula ID as shown below; and related Formula I, Formula IA, Formula IB, Formula IC, or Formula ID; Formula I, Formula IA, Formula IB, Formula IC, or Formula ID; wherein R1, R2a, R2b, R3 and R4 are as defined herein. Compounds of the Invention are useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors.

164. Substituted pyridazines as prostacyclin receptor modulators

Date: 2018-11-27 | ID: 10138210

Résumé: Cyclohexane derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

165. Non-fluorinated urethane based coatings

Date: 2018-11-27 | ID: 10138392

Résumé: A compound for imparting water repellency and optionally stain release to substrates wherein the compound is prepared by (i) reacting (a) at least one isocyanate group-containing compound selected from isocyanate, diisocyanate, polyisocyanate, or mixture thereof, and (b) at least one isocyanate-reactive compound selected from formula (Ia), (Ib), or (Ic):

166. Fitting member and replacement unit for long member

Date: 2018-11-27 | ID: 10138924

Résumé: The present invention relates to a fitting member (1) including an insertion portion (11) that fits a long member (Ia) therein and has a space through which the long member (Ia) is insertable, a movement restriction portion (14) that restricts movement that the long member (Ia) comes out of the insertion portion (11), the movement restriction portion (14) being capable of being scraped with a tool, and a guide portion (16) that guides the tool to the movement restriction portion (14) when the movement restriction portion (14) is scraped with the tool, the fitting member (1) including the movement restriction portion (14) that can be scraped with the tool to release the restriction of the movement that the long member (Ia) comes out of the insertion portion (11).

167. Automated recognition system for natural language understanding

Date: 2018-12-04 | ID: 10147419

Résumé: An interactive response system directs input to a software-based router, which is able to intelligently respond to the input by drawing on a combination of human agents, advanced recognition and expert systems. The system utilizes human intent analysts for purposes of interpreting customer input. Automated recognition subsystems are trained by coupling customer input with IA-selected intent corresponding to the input, using model-updating subsystems to develop the training information for the automated recognition subsystems.

168. Method and inverter for determining capacitance values of capacitances of an energy supply system

Date: 2018-12-04 | ID: 10148225

Résumé: A method for determining capacitance values of capacitances of a photovoltaic system including a multiphase inverter which includes an output current filter on an alternating current side thereof and is connected to a multiphase energy supply network via a switching element and is associated with at least one intermediate circuit capacitance on the direct current side thereof is provided. The method includes disconnecting the photovoltaic system from the energy supply network by opening the switching element; operating the inverter to set up an island network after the disconnecting, wherein an in-phase AC voltage is applied to at least two outputs of an inverter bridge of the multiphase inverter and a flow of current is produced between the at least one intermediate circuit capacitance and at least one filter capacitance of the output current filter; measuring currents (Ia, Ib, Ic) flowing at the outputs of the inverter bridge and at least one voltage present at one of the capacitances, and determining a capacitance value of at least one of the

capacitances using the determined voltage and the measured currents (Ia, Ib, Ic).

169. Bearer management

Date: 2018-12-04 | ID: 10149205

Résumé: A method and system of bearer management signalling in a communication network comprising of transporting bearer resource request message of both the UE and RN via DeNB to managing entity of UE within EPC, as a signalling message over uplink channel referred to as Union of Resource Request (UR Request)' message. The bearer resource response message from one of the managing entity of UE or managing entities of UE and RN within EPC are transported as a signalling message to Evolved Packet Edge (EPE) via DeNB over the downlink channel referred to as Independent Admission Response (IA Response). This manages bearer setup signalling as a single loop, by transportation of UR Request signalling message over uplink and receiving one IA Response signalling message over downlink channels. EPE is a conglomeration of network nodes comprising of UEs, RNs and all other network nodes that communicate over EPC via DeNB.

170. Indazoles and use thereof

Date: 2018-12-18 | ID: 10155752

Résumé: In one aspect, the present disclosure provides indazoles of Formula I: (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R3, R4, R5, R6, Z1, Z2, Z3, and G are defined as set forth in the specification. Further, the present disclosure also provides compounds of Formulae II and IA, and the pharmaceutically acceptable salts and solvates thereof. The present disclosure is also directed to the use of compounds of Formulae I, II, and IA, and the pharmaceutically acceptable salts and solvates thereof, to treat a disorder responsive to the blockade of sodium channels. In one embodiment, compounds of the present disclosure are especially useful for treating pain.

171. Magnetic pole position detection device of permanent magnet-type synchronous motor

Date: 2018-12-25 | ID: 10161766

Résumé: A magnetic pole position detection device of a permanent magnet-type synchronous motor detects, through a current draw-in operation, an amount of deviation between an origin of a magnetic pole position of a permanent magnet that makes up a rotor of a permanent magnet-type synchronous motor, and an origin of an output signal of a magnetic pole position sensor, and correcting the output signal of the magnetic pole position sensor on the basis of the amount of deviation, to thereby detect a true magnetic pole position. The detection device computes a phase current Ia and computes a d-axis current from the phase current Ia. The current draw-in operation is performed by causing the d-axis current to flow through armature windings of the

motor, to thereby draw the rotor to the magnetic flux axial direction.

172. Selective caspase inhibitors and uses thereof

Date: 2019-01-01 | ID: 10167313

Résumé: The present invention relates to compounds of Formula I, IA, II, IIA, III, or IIIA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).

173. Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators

Date: 2019-01-08 | ID: 10174000

Résumé: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

174. Asymmetric process for the preparation of thieno-indoles derivatives

Date: 2019-01-08 | ID: 10174048

Résumé: The present invention relates to a new process for the preparation of thieno-indole derivatives of formula (Ia) or (Ib), exploiting an asymmetric synthesis for the preparation of key (8S) or (8R) 8-(halomethyl)-1-alkyl-7,8-dihydro-6H-thieno[3,2-e]indol-4-ol intermediates, and to useful intermediate compounds of such process. Thieno-indole derivatives are described and claimed in GB2344818, WO2013/149948 and WO2013/149946, which also disclose processes for their preparation. Thieno-indole enantiopure derivatives can now be advantageously prepared through a new asymmetric synthesis of the key 8-(halomethyl)-7,8-dihydro-6H-thieno[3,2-e]indol intermediates, which, avoiding the chiral resolution step, provides benefits in terms of reducing time and costs of the whole process for their preparation. The synthesis starts from the N-alkylation of 5-amino-4-halo-3-alkyl-1-benzothiophene-7-ol derivatives with enantiopure glycidyl 3-nosylate, followed by intramolecular 6-endo-tet cyclization using alkyl Grignard reagents; Mitsunobu activation of the secondary alcohol promotes internal spirocyclization, affording the 4,4a,5,6-tetrahydro-8H-cyclopropa[c]thieno[3,2-e]indol-8-one derivatives; finally, stereo-electronically controlled regioselective cyclopropane opening yields the key enantiopure

8-(halomethyl)-1-alkyl-7,8-dihydro-6H-thieno[3,2-e]indol-4-ol intermediates, which can be further derivatized following teachings disclosed in WO2013/149948 or WO2013/149946, to prepare the final thieno-indole derivatives of formula (Ia) or (Ib). Such compounds are disclosed to be alkylating compounds with cytotoxic activity, therefore useful as such in the treatment of a variety of cancers and in cell proliferative disorders, or, conjugated with different types of nucleophiles, in the preparation of Antibody Drug Conjugated derivatives.

175. Semi-solid delivery systems

Date: 2019-01-15 | ID: 10179173

Résumé: The invention provides semi-solid systems for delivering biologically active materials that include a polymer comprising 1) one or more units of formula Ia, IIa, or IIIa: (formula Ia, IIa, IIIa) and 2) one or more units comprising polycaprolactone; wherein R and Ra have any of the values defined in the application.

176. Driver circuit for an inductor coil

Date: 2019-01-15 | ID: 10181878

Résumé: Driver circuit in which a capacitor (4), in a manner controlled by a switch control device (9) which is connected downstream of a current measuring device (8), is charged to a reference voltage (Ur) by means of a charging current (Ic2), and the charged capacitor is discharged in an oscillating manner via an inductor coil (1), wherein the discharging operation is terminated when the current (Ia) through the inductor coil has passed through an entire oscillation period or several oscillation periods, wherein a first controllable switch (5) is connected in series between a first non-reactive resistor (6) and the first capacitor (4) in one of two input paths. Furthermore, a second controllable switch (7) and a fourth controllable switch (14) are connected into two output paths, and a second non-reactive resistor (13) is connected between a second connection (X2) of the inductor coil (1) and a connection for a reference potential (Um). The current measuring device (8) is connected between the fourth controllable switch (14) and the first capacitor (4).

177. Pyrimidinone derivative having autotaxin-inhibitory activity

Date: 2019-01-22 | ID: 10183949

Résumé: A compound according to any one of formula (Ia) to (Ic), or its pharmaceutically acceptable salt:

178. Thienopyrroles as histone demethylase inhibitors

Date: 2019-01-22 | ID: 10183952

Résumé: The present application relates to thienopyrrole derivatives, compounds of Formulas (I) and (Ia), wherein R, R1, R2 and R3 are as defined in the specification, pharmaceutical compositions containing such compounds and to their use in therapy. The compounds of the application can be useful for inhibiting KDM1

and the prevention and/or treatment of cancer, infectious disease, or a disease characterized by aberration of cellular energy metabolism, e.g., obesity.

179. Polyfunctional compounds

Date: 2019-01-29 | ID: 10189783

Résumé: The present invention relates to a an imide compound according to anyone of formulas Ia, Ib, Ic, or Ie wherein R1 is H or a C1-C20 optionally substituted hydrocarbon group; both R2 and R5 are a COOH group or one of R2 and R5 is a COOH group while the other substituent is H, methyl or ethyl group; R3 and R4 are independently H, or C1-C20 optionally substituted hydrocarbon group; R6 is H or a methyl group; R7 and R8 are independently H, methyl or ethyl.

180. ROR gamma (ROR) modulators

Date: 2019-02-05 | ID: 10196350

Résumé: The present application relates to compounds according to (Formula IA) or (Formula IB): The compounds can be used as inhibitors of ROR and are useful for the treatment of ROR mediated diseases.

181. Method for analyzing signals providing instantaneous frequencies and sliding Fourier transforms, and device for analyzing signals

Date: 2019-02-12 | ID: 10204076

Résumé: The present invention is relative to a method for analyzing an signal (INS), representative of a wave that propagates in a physical medium, providing characteristic parameters of said signal, said method being implemented on a computing platform (CP), requiring only fixed point computations, and with a reduced number of multiplications. Parameters that are provided can be one or several of the following: instantaneous phase (IP), instantaneous amplitude (IA), instantaneous frequency (IF), Sliding Fourier Transform (STFT).

182. Sustained release formulation and tablets prepared therefrom

Date: 2019-02-19 | ID: 10207002

Résumé: Disclosed are formulations and tablets made therefrom comprising the compound of Formula IA or Formula IB which have sustained-release properties, and the dispersion containing the compounds of Formula IA or IB which facilitates such sustained release: Formula IA, Formula IB.

183. Macrocycles as factor XIa inhibitors

Date: 2019-02-19 | ID: 10208068

Résumé: The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a

pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

184. Tire member manufacturing method and tire manufacturing method

Date: 2019-02-19 | ID: 10208137

Résumé: A first tire member manufacturing method includes an operation in which a pre-coagulation rubber latex containing carbon black, for which a ratio of specific surface area as determined by nitrogen adsorption N2SA (in units of m2/g) to an amount of iodine absorption IA (in units of mg/g) is not less than 1.00, is coagulated to obtain a coagulum; an operation in which a compound according to Formula (I), below, is added to the water-containing coagulum; and an operation in which the compound according to Formula (I), below, is dispersed within the coagulum.In Formula (I), R1 and R2 each indicates a hydrogen atom, an alkyl group having 1 to 20 carbons, an alkenyl group having 1 to 20 carbons, or an alkynyl group having 1 to 20 carbons, R1 and R2 may be the same or different, and M+ indicates sodium ion, potassium ion, or lithium ion.

185. Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto

Date: 2019-02-26 | ID: 10214518

Résumé: Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

186. Phosphatidylinositol 3-kinase inhibitors

Date: 2019-02-26 | ID: 10214519

Résumé: The present application provides the compounds of formula I or IA

187. Group B Streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof

Date: 2019-03-12 | ID: 10226525

Résumé: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

188. Diagnosis and treatment of invasive aspergillosis

Date: 2019-03-12 | ID: 10227629

Résumé: Methods for diagnosing, treating, and monitoring the treatment of invasive aspergillosis (IA) are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having IA.

189. Harmonic current compensator and air-conditioning system

Date: 2019-04-02 | ID: 10250037

Résumé: A harmonic current compensator is connected in parallel with a harmonic generating load to a system power supply and supplies a compensation current Ia to limit a harmonic component contained in a load current IL to be input from the system power supply to the harmonic generating load. The harmonic current compensator includes: a load current detector that detects the load current IL; a compensation current detector that detects the supplied compensation current Ia; a control amount computing portion that computes a control amount of the compensation current Ia based on the harmonic component contained in the load current IL detected by the load current detector and the compensation current Ia detected by the compensation current detector; and a limiter that limits an upper limit of the compensation current Ia.

190. System and method for intelligent assistant service

Date: 2019-04-02 | ID: 10251115

Résumé: Artificial intelligence-based, intelligent agent (IA) services may include an IA server assisting users of a wireless network in various communication scenarios (e.g., calls, texts, chats, etc.). A user may specify rules for managing communications directed to a User Equipment (UE) of the user. Examples of such rules may include intercepting an incoming call to the user, managing the call based on whether the user is available, determining a reason for an incoming call and notifying the user about the reason, inviting the user to join the call, adding other users to the call, recording portions of the call, providing requested information, taking notes, scheduling meetings, and providing other assistant-type services, etc. The IA services may also include monitoring, interpreting, and responding to information that is sent to, or by, the user, during a communication, in addition to implementing Machine Learning procedures for self-improvement.

191. Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging

Date: 2019-04-09 | ID: 10253020

Résumé: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where:

192. Liquid crystal material

Date: 2019-04-16 | ID: 10260001

Résumé: The present application relates to a liquid-crystalline material which comprises at least one dye compound and at least one compound of a formula (IA) or (IB). The liquid-crystalline material is suitable for use in optical switching devices, in particular in devices for the homogeneous regulation of the passage of light through an area.

193. Pharmaceutical composition comprising nanoparticles, preparation and uses thereof

Date: 2019-04-23 | ID: 10265406

Résumé: The present application relates to a pharmaceutical composition comprising biocompatible nanoparticles or nanoparticles aggregates which allows the appropriate delivery of said biocompatible nanoparticles or nanoparticles aggregates to a target site in a subject in need thereof. The composition indeed allows an accumulation of the biocompatible nanoparticles or nanoparticles aggregates it comprises into the targeted tissue of the subject of at least 4 milligram (mg) nanoparticles or nanoparticles aggregates per gram (g) of targeted tissue when at least 0.1 g of the pharmaceutical composition per kilogram (kg) of body weight is injected intravenously (IV) or intraarterially (IA) into said subject.

194. Process for the preparation of thietane derivatives

Date: 2019-04-23 | ID: 10266524

Résumé: The present invention relates to processes for the preparation of thietane derivatives of the formula IA and thietane derivatives of the formula IB wherein R1, R2, A1, A2, A3, A4, B, and n are as defined in the claims. The invention also relates to intermediates useful in the processes, as well as the compounds of formula IA and IB and their use as pesticides.

195. Polymorph of Syk inhibitors

Date: 2019-04-23 | ID: 10266539

Résumé: Polymorphs of a bis-mesylate salt of a compound of Formula I: or a hydrate thereof, are provided. The bis-mesylate salt may also be depicted as a compound of Formula IA: Provided herein are also compositions thereof, methods for their preparation and methods for such polymorphs.

196. BCL-3 inhibitors

Date: 2019-04-30 | ID: 10273218

Résumé: The present application relates to compounds of any one of Formulae I, Ia, Ib, Ic, Id, Ie, and If. Compounds of Formula (I) have the structure:

197. Macrocyclic factor XIa inhibitors bearing heterocyclic groups

Date: 2019-04-30 | ID: 10273236

Résumé: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

198. Substituted dihydropyrrolopyrazole derivative

Date: 2019-04-30 | ID: 10273252

Résumé: The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a C1-3 alkyl group or the like; and R1, R2 and R3 each independently represent an optionally substituted linear or branched C1-4 alkyl group.

199. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase

inhibitors

Date: 2019-05-07 | ID: 10280176

Résumé: Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

200. Methods for the synthesis of functionalized nucleic acids

Date: 2019-05-07 | ID: 10280192

Résumé: The present application, among other things, provides technologies, e.g., reagents, methods, etc. for preparing oligonucleotides comprising phosphorothiotriesters linkages. In some embodiments, provided methods comprise reacting an H-phosphonate of structure Ia or Ib with a silylating reagent to provide a silyloxyphosphonate, and reacting the silyloxyphosphonate with a thiosulfonate reagent of structure IIa or IIb to provide an oligonucleotide of structure IIIa or IIIb. In some embodiments, provided methods comprise reacting an H-phosphonate of structure Ic with a silylating reagent to provide a silyloxyphosphonate, reacting the silyloxyphosphonate with a bis(thiosulfonate) reagent of structure IVc to provide a phosphorothiotriester comprising a thiosulfonate group of structure Vc, and then reacting the phosphorothiotriester comprising a thiosulfonate group of structure Vc with a nucleophile of structure VIc to provide an oligonucleotide of structure IIIc. In some embodiments, the present application provides a thiosulfonate reagent of structure IIa: